BioFire FilmArray未检出菌血症患者的抗菌药物管理机会
本研究回顾15个月内血培养阳性患者,按BioFire BCID阴性或阳性分组比较。6%阳性血培养为BCID阴性,以厌氧菌为主(57%),其病原鉴定延迟2天、有效治疗比例更低、感染死亡率更高(26% vs 8%)。提示需将厌氧菌纳入快速诊断平台以促进及时有效治疗。
要点
- BioFire BCID阴性血培养占6%,厌氧菌占57%。
- BCID阴性组病原鉴定延迟2天,有效治疗比例更低。
- BCID阴性组感染死亡率26%,高于阳性组8%。
核心结论
- BioFire BCID未检出的菌血症以厌氧菌为主,与病原鉴定延迟、有效治疗减少和感染死亡率增高相关。
- 有必要将厌氧菌纳入BioFire BCID或其他快速诊断平台以促进及时有效治疗。
研究设计与样本
- 回顾性研究,纳入15个月内至少1次血培养阳性的患者,按BioFire BCID阴性或阳性分组比较人口学、感染特征、抗生素治疗和结局。
- 共1044次阳性血培养,其中6%为BCID阴性;总体平均年龄65±22岁,54%为男性。
主要发现
- BCID阴性组糖尿病比例低于阳性组(19% vs 31%,P=0.0469),ICU入住数据相似。
- BCID阴性组57%经传统方法鉴定为厌氧菌:拟杆菌属30%、梭菌属11%、梭杆菌属8%。
- BCID阴性组病原最终鉴定延迟2天(P<0.01)。
- BCID阴性组感染源更多为不明(32% vs 11%,P<0.01)和盆腔来源(5% vs 0.1%,P<0.01),阳性组更多为尿路来源(31% vs 9%,P<0.01)。
- BCID阴性组BCID结果前(68% vs 84%,P=0.017)和结果后(82% vs 96%,P=0.0048)接受有效治疗的比例均更低;中位住院时间相似(7天),但感染死亡比例更高(26% vs 8%,P<0.01)。
临床怎么用
- 对BioFire BCID阴性但血培养阳性的患者,应警惕厌氧菌感染可能。
- 此类患者需关注盆腔或不明来源感染,并尽早评估有效覆盖厌氧菌的治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A subset of bacteremia cases are caused by organisms not detected by a rapid-diagnostics platform, BioFire blood culture identification (BCID), with unknown clinical characteristics and outcomes. Patients with ≥1 positive blood culture over a 15-month period were grouped by negative (NB-PC) versus positive (PB-PC) BioFire BCID results and compared with respect to demographics, infection characteristics, antibiotic therapy, and outcomes (length of hospital stay [LOS] and in-hospital mortality). Six percent of 1,044 positive blood cultures were NB-PC. The overall mean age was 65 ± 22 years, 54% of the patients were male, and most were admitted from home; fewer NB-PC had diabetes (19% versus 31%, P = 0.0469), although the intensive care unit admission data were similar. Anaerobes were identified in 57% of the bacteremia cases from the NB-PC group by conventional methods: Bacteroides spp. (30%), Clostridium (11%), and Fusobacterium spp. (8%). Final identification of the NB-PC pathogen was delayed by 2 days (P < 0.01) versus the PB-PC group. The sources of bacteremia were more frequently unknown for the NB-PC group (32% versus 11%, P < 0.01) and of pelvic origin (5% versus 0.1%, P < 0.01) compared to urine (31% versus 9%, P < 0.01) for the PB-PC patients. Fewer NB-PC patients received effective treatment before (68% versus 84%, P = 0.017) and after BCID results (82% versus 96%, P = 0.0048). The median LOS was similar (7 days), but more NB-PC patients died from infection (26% versus 8%, P < 0.01). Our findings affirm the need for the inclusion of anaerobes in BioFire BCID or other rapid diagnostic platforms to facilitate the prompt initiation of effective therapy for bacteremia.
引用
- Ny P, Ozaki A, Pallares J, et al. Antimicrobial Stewardship Opportunities in Patients with Bacteremia Not Identified by BioFire FilmArray. J Clin Microbiol. 2019. PMID: 30814265. doi:10.1128/JCM.01941-18
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。